River Global Investors LLP Has $1.39 Million Holdings in Gilead Sciences, Inc. (NASDAQ:GILD)

River Global Investors LLP decreased its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 0.9% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 17,182 shares of the biopharmaceutical company’s stock after selling 158 shares during the quarter. River Global Investors LLP’s holdings in Gilead Sciences were worth $1,392,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds also recently modified their holdings of GILD. Altfest L J & Co. Inc. bought a new stake in shares of Gilead Sciences during the fourth quarter valued at approximately $210,000. Federated Hermes Inc. increased its stake in Gilead Sciences by 4.9% during the 4th quarter. Federated Hermes Inc. now owns 3,787,355 shares of the biopharmaceutical company’s stock valued at $306,814,000 after purchasing an additional 175,925 shares in the last quarter. Wetzel Investment Advisors Inc. acquired a new position in Gilead Sciences during the fourth quarter worth $74,000. Abundance Wealth Counselors bought a new position in shares of Gilead Sciences in the third quarter valued at $1,881,000. Finally, HTLF Bank acquired a new position in shares of Gilead Sciences during the fourth quarter valued at about $253,000. Institutional investors own 83.67% of the company’s stock.

Gilead Sciences Stock Performance

Shares of GILD traded down $0.55 during mid-day trading on Friday, hitting $64.78. The stock had a trading volume of 7,822,720 shares, compared to its average volume of 7,345,331. Gilead Sciences, Inc. has a 52 week low of $64.33 and a 52 week high of $87.86. The company has a debt-to-equity ratio of 1.08, a current ratio of 0.98 and a quick ratio of 0.72. The business has a fifty day moving average price of $70.55 and a 200-day moving average price of $75.78. The firm has a market cap of $80.66 billion, a P/E ratio of 179.94, a PEG ratio of 1.30 and a beta of 0.22.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings data on Thursday, April 25th. The biopharmaceutical company reported ($1.32) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.49) by $0.17. The business had revenue of $6.69 billion for the quarter, compared to analysts’ expectations of $6.36 billion. Gilead Sciences had a return on equity of 24.34% and a net margin of 1.76%. The firm’s quarterly revenue was up 5.3% compared to the same quarter last year. During the same period in the previous year, the business posted $1.37 EPS. On average, equities research analysts expect that Gilead Sciences, Inc. will post 3.74 EPS for the current year.

Gilead Sciences Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, June 27th. Investors of record on Friday, June 14th will be paid a $0.77 dividend. The ex-dividend date is Friday, June 14th. This represents a $3.08 dividend on an annualized basis and a yield of 4.75%. Gilead Sciences’s dividend payout ratio is 855.56%.

Analyst Ratings Changes

GILD has been the topic of several recent research reports. Royal Bank of Canada dropped their price target on shares of Gilead Sciences from $76.00 to $74.00 and set a “sector perform” rating on the stock in a research report on Friday, April 26th. Morgan Stanley cut their target price on Gilead Sciences from $80.00 to $78.00 and set an “equal weight” rating on the stock in a research report on Friday, April 26th. Cantor Fitzgerald lowered their price target on Gilead Sciences from $80.00 to $78.00 and set a “neutral” rating for the company in a research report on Wednesday, February 7th. Barclays cut their price objective on shares of Gilead Sciences from $80.00 to $76.00 and set an “equal weight” rating on the stock in a report on Monday, April 29th. Finally, Oppenheimer reiterated an “outperform” rating and issued a $105.00 target price on shares of Gilead Sciences in a report on Friday, April 19th. Eleven analysts have rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, Gilead Sciences has an average rating of “Hold” and a consensus target price of $83.69.

Insider Buying and Selling at Gilead Sciences

In related news, insider Merdad Parsey sold 2,000 shares of the business’s stock in a transaction on Wednesday, February 28th. The stock was sold at an average price of $73.18, for a total transaction of $146,360.00. Following the sale, the insider now directly owns 100,936 shares in the company, valued at approximately $7,386,496.48. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Insiders own 0.16% of the company’s stock.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.